MALVERN, Pa., March 21, 2022 (Globe NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-phase biopharmaceutical corporation centered on identifying, developing, and commercializing gene therapies to cure blindness ailments and acquiring a vaccine to conserve lives from COVID-19, right now declared the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the role efficient March 18, 2022.
In this part, she will be responsible for the advancement and execution of the Company’s money technique, as effectively as all corporate finance, accounting, and internal and exterior economic reporting functions. She will serve as a member of Ocugen’s management team, reporting directly to the CEO.
Ms. Crespo has extra than 20 yrs of practical experience in accounting and fiscal management. She has been with Ocugen given that 2019, previously serving as Vice President, Corporate Controller and Treasurer. Just before signing up for the Firm, she held monetary leadership roles inside of Aerie Pharmaceuticals, Aralez Prescribed drugs and Cubist Prescription drugs where by she was liable for monetary and specialized accounting and SEC reporting, which includes the implementation of new accounting expectations and the accounting and reporting of complex transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance practice.
“Jess has been an essential member of the Ocugen workforce for approximately 3 several years and we are happy to realize her precious contributions with this growth of her part. The Corporation has observed transformational development more than the earlier calendar year, as we function to advance the therapies in our pipeline towards regulatory acceptance. Jess’ know-how and skills will enable us maintain that momentum,” mentioned Dr. Shankar Musunuri, Chairman of the Board, Chief Govt Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston College and is a Licensed Community Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a clinical-phase biopharmaceutical company targeted on identifying, developing, and commercializing gene therapies to cure blindness illnesses and producing a vaccine to preserve lives from COVID-19. Our breakthrough modifier gene remedy system has the prospective to treat multiple retinal ailments with 1 drug — “one to a lot of,” and our novel biologic solution applicant aims to provide better treatment to patients with underserved ailments these kinds of as damp age-connected macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-acquiring Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For far more info, remember to stop by www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press launch contains ahead-on the lookout statements within just the that means of The Private Securities Litigation Reform Act of 1995, which are subject matter to pitfalls and uncertainties. We may, in some cases, use conditions such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other phrases that express uncertainty of upcoming activities or outcomes to detect these forward-looking statements. This sort of statements are subject matter to quite a few critical components, threats and uncertainties that may well cause true functions or final results to differ materially from our present expectations. These and other dangers and uncertainties are a lot more thoroughly described in our periodic filings with the Securities and Trade Commission (“SEC”), including the risk things described in the segment entitled “Risk Factors” in the quarterly and yearly experiences that we file with the SEC. Any forward-hunting statements that we make in this push launch discuss only as of the date of this press release. Apart from as demanded by legislation, we presume no obligation to update forward-looking statements contained in this press release no matter whether as a final result of new facts, upcoming events or usually, following the date of this push launch.
Ocugen Get in touch with:
Ken Inchausti
Head, Trader Relations & Communications
[email protected]
